Fulton Bank reduced its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 9.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The hedge fund owned 3,742 shares of the medical research company’s stock after selling 388 shares during the period. Fulton Bank’s holdings in Amgen were worth $608,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Northcoast Asset Management acquired a new stake in Amgen during the third quarter worth about $54,900,000. Meag Munich Ergo Kapitalanlagegesellschaft boosted its stake in Amgen by 10.5% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft now owns 135,770 shares of the medical research company’s stock worth $18,649,000 after buying an additional 12,937 shares during the last quarter. Gerstein Fisher boosted its stake in Amgen by 1.0% in the third quarter. Gerstein Fisher now owns 9,359 shares of the medical research company’s stock worth $1,294,000 after buying an additional 97 shares during the last quarter. Eagle Asset Management boosted its stake in Amgen by 83.2% in the third quarter. Eagle Asset Management now owns 59,812 shares of the medical research company’s stock worth $8,272,000 after buying an additional 27,168 shares during the last quarter. Finally, TrimTabs Asset Management acquired a new stake in Amgen during the third quarter worth about $2,021,000.

Amgen, Inc. (NASDAQ:AMGN) traded down 1.41% on Thursday, reaching $148.35. The company’s stock had a trading volume of 4,246,491 shares. The firm has a market cap of $111.90 billion and a price-to-earnings ratio of 17.71. Amgen, Inc. has a 12 month low of $130.09 and a 12 month high of $181.81. The firm has a 50 day moving average of $156.56 and a 200 day moving average of $156.97.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, January 28th. The medical research company reported $2.61 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.29 by $0.32. During the same quarter in the prior year, the firm earned $2.16 EPS. The firm had revenue of $5.54 billion for the quarter, compared to the consensus estimate of $5.53 billion. The company’s revenue was up 3.8% compared to the same quarter last year. Analysts anticipate that Amgen, Inc. will post $10.08 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 8th. Investors of record on Tuesday, February 16th will be issued a dividend of $1.00 per share. The ex-dividend date of this dividend is Thursday, February 11th. This represents a $4.00 annualized dividend and a yield of 2.70%. This is a boost from Amgen’s previous quarterly dividend of $0.47.

A number of analysts recently issued reports on AMGN shares. Vetr cut Amgen from a “strong-buy” rating to a “buy” rating and set a $166.85 target price for the company. in a research note on Monday, October 12th. Piper Jaffray reissued an “overweight” rating and set a $200.00 target price on shares of Amgen in a research note on Monday, October 12th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Amgen in a research note on Thursday, October 29th. Finally, Morgan Stanley increased their target price on Amgen to $160.00 in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $184.88.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

12 Month Chart for NASDAQ:AMGN

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.